Related Experiment Video
Updated: Aug 12, 2025

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
Published on: May 25, 2018
CAS12e (CASX2) CLEAVAGE OF CCR5: IMPACT OF GUIDE RNA LENGTH AND PAM SEQUENCE ON CLEAVAGE ACTIVITY
David A Armstrong1,2,3, Taylor R Hudson1, Christine A Hodge2,3
1Research Service, V.A. Medical Center, White River Junction, VT, USA, 05001.
Abstract:
CRISPR/Cas is under development as a therapeutic tool for the cleavage, excision, and/or modification of genes in eukaryotic cells. While much effort has focused on CRISPR/Cas from Streptococcus pyogenes (SpCas9) and Staphylococcus aureus (SaCas9), alternative CRISPR systems have been identified using metagenomic datasets from non-pathogenic microbes, including previously unknown class 2 systems, adding to a diverse toolbox of gene editors. The Cas12e (CasX1, CasX2) endonucleases from non-pathogenic Deltaproteobacteria (DpeCas12e) and Planctomycetes (PlmCas12e) are more compact than SpCas9, have a more selective protospacer adjacent motif (PAM) requirement, and deliver a staggered cleavage cut with 5-7 base overhangs. We investigated varying guide RNA (spacer) lengths and alternative PAM sequences to determine optimal conditions for PlmCas12e cleavage of the cellular gene CCR5 (CC-Chemokine receptor-5). CCR5 encodes one of two chemokine coreceptors required by HIV-1 to infect target cells, and a mutation of CCR5 (delta-32) is responsible for HIV-1 resistance and reported cures following bone marrow transplantation. Consequently, CCR5 has been an important target for gene editing utilizing CRISPR, TALENs, and ZFNs. We determined that CCR5 cleavage activity varied with the target site, guide RNA length, and the terminal nucleotide in the PAM sequence. Our analyses demonstrated a PlmCas12e PAM preference for purines (A, G) over pyrimidines (T, C) in the fourth position of the CasX2 PAM (TTCN). These analyses have contributed to a better understanding of CasX2 cleavage requirements and will position us more favorably to develop a therapeutic that creates the delta-32 mutation in the CCR5 gene in hematopoietic stem cells.
Insights
Researchers optimized the PlmCas12e gene editing system for targeting the CCR5 gene. This advancement aids in developing therapies for HIV-1 resistance by understanding CasX2 cleavage requirements.
Area of Science:
- Molecular Biology
- Gene Editing
- Microbiology
Background:
- CRISPR/Cas systems are evolving as therapeutic gene editing tools.
- Alternative CRISPR systems, including compact Cas12e, offer diverse gene editing capabilities.
- The CCR5 gene is a key target for HIV-1 resistance gene therapies.
Approach:
- Investigated PlmCas12e (CasX2) endonuclease activity.
- Optimized guide RNA lengths and protospacer adjacent motif (PAM) sequences for CCR5 gene cleavage.
- Analyzed PlmCas12e cleavage variations based on target site, guide RNA length, and PAM sequence.
Key Points:
- PlmCas12e exhibits a PAM preference for purines (A, G) over pyrimidines (T, C) at the fourth position of the TTCN PAM.
- Cleavage efficiency is influenced by target site, guide RNA length, and PAM terminal nucleotide.
- Understanding CasX2 cleavage requirements is crucial for developing CCR5-targeted gene therapies.
Conclusions:
- Optimized PlmCas12e conditions enhance its utility for gene editing applications.
- This research advances the development of therapies aimed at conferring HIV-1 resistance via CCR5 gene modification.
- The findings contribute to the broader field of CRISPR-based gene therapeutics.

